
Lung Cancer
Labcorp Oncology offers a comprehensive test menu to assist in the diagnosis and management of patients with lung cancer throughout their continuum of care.

Diagnostic
Diagnostic
Complex Tumor Analysis by IHC
Our extensive antibody library and team of pathologists can provide a differential diagnostic analysis in even the most difficult cases.
- Squamous cell vs. adenocarcinoma
- Adenocarcinoma vs. Mesothelioma
- Lung vs. Breast
- Small cell vs. non-small cell carcinoma
Prognostic
Prognostic
KRAS Gene Mutation
Analysis, IVD
The presence of a KRAS mutation is prognostic for poor survival.1
Predictive
Predictive biomarkers for therapeutic selection
Test | Detects | Therapy |
---|---|---|
ALK (D5F3) by IHC | ALK protein expression | alectinib2, brigatinib3, lorlatinib4, ceritinib5, crizotinib6 |
ALK by FISH | ALK rearrangements (translocations) | alectinib2, brigatinib3, lorlatinib4, ceritinib5, crizotinib6 |
BRAF Gene Mutation Analysis | Mutations in the BRAF gene (V600E) | dabrafenib7 +/ trametinib8, vemurafenib9 |
EGFR Mutation Analysis Cobas V2 Assay (Plasma) | Mutations in the EGFR gene | osimertinib10, gefitinib11, erlotinib12, afatinib13,dacomitinib14 |
EGFR Mutation Analysis | Mutations in the EGFR gene | osimertinib10, gefitinib11, erlotinib12, afatinib13,dacomitinib14 |
EGFR by FISH | EGFR amplification | osimertinib10, gefitinib11, erlotinib12, afatinib13,dacomitinib14 |
KRAS Mutation Analysis, IVD | Mutations in the KRAS gene (G12C) | sotorasib15 |
MET by FISH | MET amplification | crizotinib6 |
OmniSeq INSIGHT, Solid Tumor NGS Panel (DNA and RNA) | Next-generation sequencing panel of DNA and RNA (523 genes) and relevant immune biomarkers including PD-L1 IHC, MSI, TMB | Targeted therapies and immunotherapies |
PD-L1 by IHC (SP263, SP142, 28-8 clones) | PD-L1 protein expression | pembrolizumab16, nivolumab17, atezolizumab18 |
Resolution ctDx Lung Assay (Liquid Biopsy) | 23 actionable genes associated with biomarker directed therapy in NSCLC | Targeted therapies |
RET by FISH | RET rearrangements (translocations) | selpercatinib19, pralsetinib20, cabozantinib21 |
ROS1 by FISH | ROS1 rearrangements (translocations) | crizotinib6, ceritinib5, entrectinib22 |
References
- Slebos, R.J., et al., K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990 Aug 30;323(9):561-5.
- ALECENSA® (alectinib) [package insert]. South San Francisco, CA: Genentech, Inc.; 2021.
- ALUNBRIGTM (brigatinib) [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; 2017.
- LORBRENA® (lorlatinib) [package insert]. New York, NY: Pfizer, Inc.; 2021.
- ZYKADIA® (ceritinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019.
- XALKORI® (crizotinib) [package insert]. New York, NY: Pfizer, Inc.; 2022.
- TAFINLAR® (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.
- MEKINIST® (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2022.
- ZELBORAF® (vemurafenib) [package insert]. South San Francisco, CA: Genentech, Inc.; 2021.
- TAGRISSO® (osimertinib) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.
- IRESSA® (gefitinib) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2021.
- TARCEVA® (erlotinib) [package insert]. South San Francisco, CA: Genentech, Inc.; 2010.
- GILOTRIF® (afatinib) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2018.
- VIZIMPRO® (dacomitinib) [package insert]. New York, NY: Pfizer, Inc.; 2018.
- LUMAKRAS™ (sotorasib) [package insert]. Thousand Oaks, CA: Amgen Inc.; 2021.
- KEYTRUDA® (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck &Co., Inc.; 2021.
- OPDIVO® (nivolumab) [package insert]. Princeton, NJ: : Bristol-Myers Squibb Company; 2018.
- TECENTRIQ® (atezolizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2018.
- RETEVMO™ (selpercatinib) [package insert]. Indianapolis, IN: Lilly USA, LLC; 2021.
- GAVRETO™ (pralsetinib) [package insert]. Cambridge, MA: : Blueprint Medicines Corporation; 2020.
- CABOMETYX® (cabozantinib) [package insert]. Alameda, CA: Exelixis, Inc.; 2019.
- ROZLYTREK™ (entrectinib) [package insert]. South San Francisco, CA: Genentech, Inc.; 2019.